UK begins trial of latest vaccine candidate for coronavirus

LONDON (AP) — Scientists at Imperial College London will start immunising people in Britain this week with their experimental coronavirus shot, becoming the latest entry into the race to find an effective vaccine to stop the pandemic.

In a statement, the British government said 300 healthy people will be immunised with two doses of the COVID-19 vaccine candidate developed at Imperial, which has been backed by GBP41 million (USD51 million) in government funding.

So far, the vaccine candidate developed by Imperial College London has only been tested in animals and in the laboratory, where it produced much higher levels of antibodies than would normally be seen in infected people.

Many scientists have warned that the pandemic might only be stopped with an effective vaccine, which typically takes years to develop.

“In the long term, a viable vaccine could be vital for protecting the most vulnerable, enabling restrictions to be eased and helping people get back to normal life,” said Robin Shattock, who is leading the vaccine research.

The vaccine uses synthetic strands of genetic code based on the virus. Once injected into the muscle, the body’s own cells are instructed to make copies of a spiky protein on the coronavirus. That should in turn trigger an immune response so the body can fight off any future COVID-19 infection.

Chief Executive of the British Society for Immunology Dr Doug Brown said the particular technology used by Imperial College London should theoretically lead to long-term immunity against the coronavirus but needs to go through rigorous testing. He was not linked to the trial.

About a dozen vaccine candidates are currently in early stages of testing in thousands of people. There are no guarantees any will work but there’s increasing hope that at least some could be ready by the end of the year.